News

The Fight Against Prostate Cancer: What Men Need to Know

New York, NY – Prostate cancer is the second most common cancer among men, and it is estimated that nearly three million men are living with the disease in the United States. Thankfully, many prostate cancers can be caught early on and either successfully treated or diagnosed as indolent (non-aggressive). Early detection of prostate cancer […]

News

Prostate Cancer Awareness Month featured on Hattiesburg American News

For Prostate Cancer Awareness Month, Hattiesburg American News spoke with our client Hattiesburg Clinic Urology about the 4Kscore, a revolutionary test that predicts a man’s risk of developing aggressive prostate cancer. The test assists physicians, urologists, and nurse practitioners in making better-informed patient care decisions. Please read the full article below and see the original post […]

News

A Better Prostate Cancer Test? New Advanced Tools Help Identify Aggressive Prostate Cancer

“The goal of diagnosing and treating prostate cancer is diagnosing it early on when it’s confined to the prostate” NEW YORK, NY–(Marketwired – Sep 7, 2016) – During their lifetime approximately one in seven men will be diagnosed with prostate cancer, the second most common cancer among men in the U.S. The odds increase for […]

Press Release

OPKO to Discuss Draft Coverage Determinations for 4Kscore® Test at 2016 Jefferies Healthcare Conference

OPKO Health, Inc. (NYSE: OPK) today announced that senior management will discuss recent draft local coverage determinations by certain Medicare Administrative Contractors for OPKO’s 4Kscore® test at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT). OPKO previously announced that Novitas Solutions issued a positive draft local coverage […]

Press Release

OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination for 4Kscore® Test

OPKO Health, Inc. (NYSE:OPK) (“OPKO” or the “Company”) announces that Novitas Solutions has issued a draft local coverage determination for the 4Kscore® Test, the only blood test that accurately identifies an individual patient’s risk for high-grade, aggressive prostate cancer. Novitas Solutions is a Medicare Administrative Contractor (MAC) for Medicare jurisdictions L and H, with responsibility for nearly […]

Press Release

OPKO 4Kscore® Recommended in 2016 European Association of Urology Prostate Cancer Guidelines

OPKO Health, Inc. (NYSE:OPK) today announced the decision of the European Association of Urology (EAU) Prostate Cancer Guidelines Panel to include the 4Kscore® Test in the 2016 EAU Guidelines for Prostate Cancer. The panel concluded that the 4Kscore, as a blood test with greater specificity over the PSA test, is indicated for use prior to a first […]

Press Release

Study Demonstrates OPKO’s 4Kscore Test Reduces Unnecessary Prostate Biopsies While Improving Risk Prediction for Aggressive Prostate Cancer

OPKO Health, Inc. (NYSE: OPK) announced today the results of a study for the 4Kscore® Test’s clinical utility in reducing the number of prostate biopsies performed, while increasing the probability of detecting aggressive prostate cancer in men with abnormal prostate-specific antigen (PSA) levels and or digital rectal examination (DRE) results. The peer-reviewed study, “The 4Kscore® Test […]

News

Study Confirms 4Kscore Accurately Predicts High-Grade Prostate Cancer

A blood test called the 4Kscore results in accurate detection of high-grade prostate cancer. In a prospective study of 1,012 men, this test more accurately predicted the presence of high-grade disease compared with a commonly used risk calculator in men with elevated prostate-specific antigen (PSA) levels. The results from this study (Abstract 1) were presented […]

News

OPKO’s 4Kscore Prostate Biopsy Alternative Might Reduce Unnecessary Biopsies

ORLANDO—The 4Kscore, an algorithmic analysis of data from a blood test that combines four kallikrein assays with clinical information to identify the probability of high-grade prostate tumors, could dramatically reduce the number of unnecessary prostate biopsies, according to a multi-institutional prospective study (Abstract 1) presented during the 2015 Genitourinary Cancers Symposium.1 “The 4Kscore demonstrated excellent […]